{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T00:49:50Z","timestamp":1794962990337,"version":"4.9.1"},"reference-count":82,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revista Espa\u00f1ola de Geriatr\u00eda y Gerontolog\u00eda"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.regg.2024.101582","type":"journal-article","created":{"date-parts":[[2024,12,17]],"date-time":"2024-12-17T06:25:33Z","timestamp":1734416733000},"page":"101582","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Efficacy and safety of osteoporosis treatment in older adults. Approach for the secondary prevention of fractures in older populations. A proposal by SEFRAOS"],"prefix":"10.1016","volume":"60","author":[{"given":"Leonor","family":"Cuadra-Llopart","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Pareja Sierra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pilar","family":"S\u00e1ez-L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I\u00f1igo","family":"Etxebarria-Foronda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 R.","family":"Caeiro Rey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.regg.2024.101582_bib0415","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1007\/s11657-022-01061-5","article-title":"UK clinical guideline for the prevention and treatment of osteoporosis","volume":"1","author":"Gregson","year":"2022","journal-title":"Arch Osteoporos"},{"issue":"Suppl. 1","key":"10.1016\/j.regg.2024.101582_bib0420","article-title":"Osteoporosis in the elderly","volume":"25","author":"Seriolo","year":"2013","journal-title":"Aging Clin Exp Res"},{"key":"10.1016\/j.regg.2024.101582_bib0425","doi-asserted-by":"crossref","DOI":"10.1186\/s12891-021-04291-9","article-title":"Changing epidemiology of lower extremity fractures in adults over a 15-year period \u2013 a National Hospital Discharge Registry study","volume":"22","author":"Hemmann","year":"2021","journal-title":"BMC Musculoskelet Disord"},{"key":"10.1016\/j.regg.2024.101582_bib0430","doi-asserted-by":"crossref","first-page":"13","DOI":"10.4321\/S1889-836X2022000100003","article-title":"Gu\u00edas de pr\u00e1ctica cl\u00ednica en la osteoporosis postmenop\u00e1usica, glucocorticoidea y del var\u00f3n (actualizaci\u00f3n 2022)","volume":"14","author":"Riancho","year":"2022","journal-title":"Rev Osteoporos Metab Miner"},{"key":"10.1016\/j.regg.2024.101582_bib0435","doi-asserted-by":"crossref","DOI":"10.1007\/s11657-020-00871-9","article-title":"SCOPE 2021 a new scorecard for osteoporosis in Europe","volume":"16","author":"Kanis","year":"2021","journal-title":"Arch Osteoporos"},{"key":"10.1016\/j.regg.2024.101582_bib0440","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1056\/NEJMra2301292","article-title":"Frailty in older adults","volume":"391","author":"Kim","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.regg.2024.101582_bib0445","first-page":"226","article-title":"Prevalence of frailty at population level in European ADVANTAGE Joint Action Member States: a systematic review and meta-analysis","volume":"54","author":"O\u2019Caoimh","year":"2018","journal-title":"Ann Ist Super Sanita"},{"key":"10.1016\/j.regg.2024.101582_bib0450","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1503\/cmaj.050051","article-title":"A global clinical measure of fitness and frailty in elderly people","volume":"173","author":"Rockwood","year":"2005","journal-title":"CMAJ"},{"key":"10.1016\/j.regg.2024.101582_bib0455","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/S2213-8587(20)30159-5","article-title":"Treatment-related changes in bone mineral density as a surrogate biomarker for fracture risk reduction: meta-regression analyses of individual patient data from multiple randomised controlled trials","volume":"8","author":"Black","year":"2020","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.regg.2024.101582_bib0460","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.archger.2017.05.017","article-title":"A systematic review of trends in the selective exclusion of older participant from randomised clinical trials","volume":"72","author":"Thake","year":"2017","journal-title":"Arch Gerontol Geriatr"},{"key":"10.1016\/j.regg.2024.101582_bib0465","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1159\/000514449","article-title":"Pharmacological treatment of osteoporosis in elderly people: a systematic review and meta-analysis","volume":"67","author":"Wang","year":"2021","journal-title":"Gerontology"},{"key":"10.1016\/j.regg.2024.101582_bib0470","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1007\/s12603-022-1825-5","article-title":"Efficacy of antiresorptive treatment in osteoporotic older adults: a systematic review and meta-analysis of randomized clinical trials","volume":"26","author":"Cedeno-Veloz","year":"2022","journal-title":"J Nutr Health Aging"},{"key":"10.1016\/j.regg.2024.101582_bib0475","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.2147\/CIA.S131023","article-title":"Pharmacological treatment of osteoporosis in the oldest old","volume":"12","author":"Vandenbroucke","year":"2017","journal-title":"Clin Interv Aging"},{"key":"10.1016\/j.regg.2024.101582_bib0480","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1111\/j.1532-5415.2009.02673.x","article-title":"Efficacy and safety of a once-yearly intravenous zoledronic acid 5mg for fracture prevention in elderly postmenopausal women with osteoporosis aged 75 and older","volume":"58","author":"Boonen","year":"2010","journal-title":"J Am Geriatr Soc"},{"key":"10.1016\/j.regg.2024.101582_bib0485","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1359\/JBMR.050104","article-title":"Effect of alendronate on the age-specific incidence of symptomatic osteoporotic fractures","volume":"20","author":"Hochberg","year":"2005","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.regg.2024.101582_bib0490","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1056\/NEJM200102013440503","article-title":"Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group","volume":"344","author":"McClung","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.regg.2024.101582_bib0495","doi-asserted-by":"crossref","first-page":"2617","DOI":"10.1001\/archinte.1997.00440430099012","article-title":"Treatment with alendronate prevents fractures in women at highest risk: results from the Fracture Intervention Trial","volume":"157","author":"Ensrud","year":"1997","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.regg.2024.101582_bib0500","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1111\/joim.12678","article-title":"Hip fracture risk and safety with alendronate treatment in the oldest-old","volume":"282","author":"Axelsson","year":"2017","journal-title":"J Intern Med"},{"key":"10.1016\/j.regg.2024.101582_bib0505","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1001\/jama.282.14.1344","article-title":"Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial","volume":"282","author":"Harris","year":"1999","journal-title":"JAMA"},{"key":"10.1016\/j.regg.2024.101582_bib0510","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s001980050010","article-title":"Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis","volume":"11","author":"Reginster","year":"2000","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.regg.2024.101582_bib0515","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1111\/j.1532-5415.2004.52506.x","article-title":"Safety and efficacy of risedronate in reducing fracture risk in osteoporotic women aged 80 and older: implications for the use of antiresorptive agents in the old and oldest old","volume":"52","author":"Boonen","year":"2004","journal-title":"J Am Geriatr Soc"},{"key":"10.1016\/j.regg.2024.101582_bib0520","doi-asserted-by":"crossref","first-page":"445","DOI":"10.2147\/CIA.S8200","article-title":"Reducing hip fracture risk with risedronate in elderly women with established osteoporosis","volume":"4","author":"Masud","year":"2009","journal-title":"Clin Interv Aging"},{"key":"10.1016\/j.regg.2024.101582_bib0525","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa067312","article-title":"Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis","volume":"356","author":"Black","year":"2007","journal-title":"N Engl J Med."},{"key":"10.1016\/j.regg.2024.101582_bib0530","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1056\/NEJMoa0809493","article-title":"Denosumab for prevention of fractures in postmenopausal women with osteoporosis","volume":"361","author":"Cummings","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.regg.2024.101582_bib0535","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1002\/jbmr.536","article-title":"Effect of denosumab treatment on the risk of fractures in subgroups of women with postmenopausal osteoporosis","volume":"27","author":"McClung","year":"2012","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.regg.2024.101582_bib0540","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1210\/jc.2010-2784","article-title":"Treatment with denosumab reduces the incidence of new vertebral and hip fractures in postmenopausal women at high risk","volume":"96","author":"Boonen","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.regg.2024.101582_bib0545","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1056\/NEJM200105103441904","article-title":"Effect of parathyroid hormone (1\u201334) on fractures and bone mineral density in postmenopausal women with osteoporosis","volume":"344","author":"Neer","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.regg.2024.101582_bib0550","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1111\/j.1532-5415.2006.00695.x","article-title":"Safety and efficacy of teriparatide in elderly women with established osteoporosis: bone anabolic therapy from a geriatric perspective","volume":"54","author":"Boonen","year":"2006","journal-title":"J Am Geriatr Soc"},{"key":"10.1016\/j.regg.2024.101582_bib0555","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bone.2018.09.020","article-title":"Effects of teriparatide on hip and upper limb fractures in patients with osteoporosis: a systematic review and meta-analysis","volume":"120","author":"D\u00edez-P\u00e9rez","year":"2019","journal-title":"Bone"},{"key":"10.1016\/j.regg.2024.101582_bib0560","first-page":"3","article-title":"Comparative effectiveness and cardiovascular safety of abaloparatide and teriparatide in postmenopausal women new to anabolic therapy: a US administrative claims database study","volume":"1","author":"Cosman","year":"2022","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.regg.2024.101582_bib0565","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1097\/GME.0000000000001080","article-title":"Effects of abaloparatide on bone mineral density and risk of fracture in postmenopausal women aged 80 years or older with osteoporosis","volume":"25","author":"McClung","year":"2018","journal-title":"Menopause"},{"key":"10.1016\/j.regg.2024.101582_bib0570","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1056\/NEJMoa1607948","article-title":"Romosozumab treatment in postmenopausal women with osteoporosis","volume":"375","author":"Cosman","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.regg.2024.101582_bib0575","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1056\/NEJMoa1708322","article-title":"Romosozumab or alendronate for fracture prevention in women with osteoporosis","volume":"377","author":"Saag","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.regg.2024.101582_bib0580","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1007\/s11914-018-0464-6","article-title":"Current understanding of epidemiology pathophysiology, and management of atypical femur fractures","volume":"16","author":"Starr","year":"2018","journal-title":"Curr Osteoporos Rep"},{"key":"10.1016\/j.regg.2024.101582_bib0585","doi-asserted-by":"crossref","first-page":"2544","DOI":"10.1002\/jbmr.1719","article-title":"Incidence of atypical nontraumatic diaphyseal fractures of the femur","volume":"27","author":"Dell","year":"2012","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.regg.2024.101582_bib0590","doi-asserted-by":"crossref","DOI":"10.1186\/s12891-016-1086-8","article-title":"Management of atypical femoral fracture: a scoping review and comprehensive algorithm","volume":"17","author":"Toro","year":"2016","journal-title":"BMC Musculoskelet Disord"},{"key":"10.1016\/j.regg.2024.101582_bib0595","doi-asserted-by":"crossref","first-page":"2971","DOI":"10.1200\/JCO.19.02192","article-title":"Teriparatide promotes bone healing in medication-related osteonecrosis of the jaw: a placebo-controlled randomized trial","volume":"38","author":"Sim","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.regg.2024.101582_bib0600","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1210\/clinem\/dgab888","article-title":"Osteonecrosis of the jaw and antiresorptive agents in benign and malignant diseases: a critical review organized by the ECTS","volume":"107","author":"Anastasilakis","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.regg.2024.101582_bib0605","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s00198-020-05498-7","article-title":"Upper gastrointestinal safety of oral bisphosphonate in hospitalized patients","volume":"32","author":"Nguyen","year":"2021","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.regg.2024.101582_bib0610","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1220174","article-title":"Antiosteoporosis medications and cardiovascular disease: a population-based nationwide nested case\u2013control study","volume":"14","author":"Tsai","year":"2023","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.regg.2024.101582_bib0615","doi-asserted-by":"crossref","DOI":"10.1177\/17455057231170059","article-title":"Cardiovascular benefits and risks associated with calcium, vitamin D, and antiresorptive therapy in the management of skeletal fragility","volume":"19","author":"Kittithaworn","year":"2023","journal-title":"Womens Health (Lond Engl)"},{"key":"10.1016\/j.regg.2024.101582_bib0620","doi-asserted-by":"crossref","DOI":"10.1186\/s12891-023-06965-y","article-title":"Prediction of musculoskeletal pain after the first intravenous zoledronic acid injection in patients with primary osteoporosis: development and evaluation of a new nomogram","volume":"24","author":"Zheng","year":"2023","journal-title":"BMC Musculoskelet Disord"},{"key":"10.1016\/j.regg.2024.101582_bib0625","doi-asserted-by":"crossref","DOI":"10.1007\/s00198-023-06926-0","article-title":"Prevalence of denosumab-induced hypocalcemia: a retrospective observational study of patients routinely monitored with ionized calcium post-injection","volume":"35","author":"Sp\u00e5ngeus","year":"2024","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.regg.2024.101582_bib0630","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1007\/s00198-023-06869-6","article-title":"Atypical femoral fracture after denosumab for the treatment of osteoporosis in bisphosphonate na\u00efve patients: two further cases","volume":"34","author":"Fitzpatrick","year":"2023","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.regg.2024.101582_bib0635","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S0140-6736(15)61120-5","article-title":"Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial","volume":"386","author":"Leder","year":"2015","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.regg.2024.101582_bib0640","doi-asserted-by":"crossref","DOI":"10.1111\/ijcp.14550","article-title":"Multiple vertebral fractures after suspension of denosumab. A series of 56 cases","volume":"75","author":"Sosa-Henr\u00edquez","year":"2021","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.regg.2024.101582_bib0645","doi-asserted-by":"crossref","first-page":"2885","DOI":"10.1007\/s00198-012-1955-4","article-title":"Effects of morning vs. evening teriparatide injection on bone mineral density and bone turnover markers in postmenopausal osteoporosis","volume":"23","author":"Michalska","year":"2012","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.regg.2024.101582_bib0650","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/s00223-010-9424-6","article-title":"Pharmacokinetics of teriparatide (rhPTH[1-34]) and calcium pharmacodynamics in postmenopausal women with osteoporosis","volume":"87","author":"Satterwhite","year":"2010","journal-title":"Calcif Tissue Int."},{"key":"10.1016\/j.regg.2024.101582_bib0655","doi-asserted-by":"crossref","DOI":"10.1002\/jbm4.10665","article-title":"Teriparatide and osteosarcoma risk: history, science elimination of boxed warning, and other label updates","volume":"6","author":"Krege","year":"2022","journal-title":"JBMR Plus"},{"key":"10.1016\/j.regg.2024.101582_bib0660","first-page":"520","article-title":"Treatment of osteoporosis with anabolic agents and the risk of primary bone cancers: a study of 44,728 patients treated with teriparatide and abaloparatide","volume":"31","author":"McDonald","year":"2023","journal-title":"J Am Acad Orthop Surg"},{"key":"10.1016\/j.regg.2024.101582_bib0665","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1002\/jbmr.4188","article-title":"Teriparatide did not increase adult osteosarcoma incidence in a 15-year US Postmarketing Surveillance Study","volume":"36","author":"Gilsenan","year":"2021","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.regg.2024.101582_bib0670","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1007\/s00198-020-05718-0","article-title":"Long-term cancer surveillance: results from the Forteo Patient Registry Surveillance Study","volume":"32","author":"Gilsenan","year":"2021","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.regg.2024.101582_bib0675","doi-asserted-by":"crossref","DOI":"10.1016\/j.bone.2022.116394","article-title":"Assessing the incidence of osteosarcoma among teriparatide-treated patients using linkage of commercial pharmacy and state cancer registry data, contributing to the removal of boxed warning and other labeling changes","volume":"160","author":"Kellier-Steele","year":"2022","journal-title":"Bone"},{"key":"10.1016\/j.regg.2024.101582_bib0680","doi-asserted-by":"crossref","first-page":"3384","DOI":"10.1210\/clinem\/dgaa450","article-title":"Cardiovascular safety of abaloparatide in postmenopausal women with osteoporosis: analysis from the ACTIVE Phase 3 Trial","volume":"105","author":"Cosman","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.regg.2024.101582_bib0685","article-title":"Bisphosphonates and risk of cardiovascular events: a meta-analysis","volume":"10","author":"Kim","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.regg.2024.101582_bib0690","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1007\/s00198-020-05379-z","article-title":"Explanations for the difference in rates of cardiovascular events in a trial of alendronate and romosozumab","volume":"31","author":"Cummings","year":"2020","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.regg.2024.101582_bib0695","doi-asserted-by":"crossref","DOI":"10.3390\/jcm10143043","article-title":"Efficacy and safety of postmenopausal osteoporosis treatments: a systematic review and network meta-analysis of randomized controlled trials","volume":"10","author":"Lin","year":"2021","journal-title":"J Clin Med"},{"key":"10.1016\/j.regg.2024.101582_bib0700","series-title":"Clinical guideline for the prevention and treatment osteoporosis","year":"2021"},{"key":"10.1016\/j.regg.2024.101582_bib0705","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.semreu.2009.09.002","article-title":"Osteoporosis secundaria a f\u00e1rmacos","volume":"10","author":"Sall\u00e9s","year":"2009","journal-title":"Semin la Fund Espa\u00f1ola Reumatol"},{"key":"10.1016\/j.regg.2024.101582_bib0710","doi-asserted-by":"crossref","DOI":"10.1093\/ageing\/afac044","article-title":"New national osteoporosis guidance-implications for geriatricians","volume":"51","author":"Gregson","year":"2022","journal-title":"Age Ageing"},{"key":"10.1016\/j.regg.2024.101582_bib0715","series-title":"Orthogeriatrics: the management of older patients with fragility fractures [Internet]","author":"Falaschi","year":"2021"},{"key":"10.1016\/j.regg.2024.101582_bib0720","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.clnu.2018.08.002","article-title":"GLIM criteria for the diagnosis of malnutrition \u2013 a consensus report from the global clinical nutrition community","volume":"38","author":"Cederholm","year":"2019","journal-title":"Clin Nutr"},{"key":"10.1016\/j.regg.2024.101582_bib0725","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1002\/jcsm.12567","article-title":"Osteosarcopenia: epidemiology, diagnosis, and treatment \u2013 facts and numbers","volume":"11","author":"Kirk","year":"2020","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"10.1016\/j.regg.2024.101582_bib0730","doi-asserted-by":"crossref","DOI":"10.1093\/ageing\/afac205","article-title":"World guidelines for falls prevention and management for older adults: a global initiative","volume":"51","author":"Montero-Odasso","year":"2022","journal-title":"Age Ageing"},{"issue":"Spec No. 2","key":"10.1016\/j.regg.2024.101582_bib0735","first-page":"50","article-title":"Multicomponent physical exercise program: Vivifrail","volume":"36","author":"Izquierdo","year":"2019","journal-title":"Nutr Hosp"},{"key":"10.1016\/j.regg.2024.101582_bib0740","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1007\/s00198-019-05228-8","article-title":"Persistence and compliance with osteoporosis therapies among postmenopausal women in the UK Clinical Practice Research Datalink","volume":"31","author":"Morley","year":"2020","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.regg.2024.101582_bib0745","doi-asserted-by":"crossref","DOI":"10.1177\/2151459320979978","article-title":"The clinical impact of fracture liaison services: a systematic review","volume":"12","author":"Barton","year":"2021","journal-title":"Geriatr Orthop Surg Rehabil"},{"key":"10.1016\/j.regg.2024.101582_bib0750","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1007\/s00198-015-3443-0","article-title":"Evidence of effectiveness of a fracture liaison service to reduce the re-fracture rate","volume":"27","author":"Nakayama","year":"2016","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.regg.2024.101582_bib0755","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1007\/s00198-020-05803-4","article-title":"The effect on subsequent fracture risk of age, sex, and prior fracture site by recency of prior fracture","volume":"32","author":"Kanis","year":"2021","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.regg.2024.101582_bib0760","series-title":"SECOT-SEGG. Guia SECOT-SEGG de Osteoporosis y Fractura Por Fragidad","year":"2022"},{"key":"10.1016\/j.regg.2024.101582_bib0765","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.eprac.2024.01.014","article-title":"Treatment sequence for osteoporosis","volume":"30","author":"Cosman","year":"2024","journal-title":"Endocr Pract"},{"key":"10.1016\/j.regg.2024.101582_bib0770","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1056\/NEJMoa050336","article-title":"One year of alendronate after one year of parathyroid hormone (1\u201384) for osteoporosis","volume":"353","author":"Black","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.regg.2024.101582_bib0775","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1002\/jbmr.3051","article-title":"Treatment sequence matters: anabolic and antiresorptive therapy for osteoporosis","volume":"32","author":"Cosman","year":"2017","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.regg.2024.101582_bib0780","doi-asserted-by":"crossref","first-page":"2949","DOI":"10.1210\/jc.2018-00163","article-title":"ACTIVExtend: 24 months of alendronate after 18 months of abaloparatide or placebo for postmenopausal osteoporosis","volume":"103","author":"Bone","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.regg.2024.101582_bib0785","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1210\/jc.2016-1160","article-title":"Effects of two years of teriparatide denosumab, or both on bone microarchitecture and strength (DATA-HRpQCT study)","volume":"101","author":"Tsai","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.regg.2024.101582_bib0790","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1002\/jbmr.3622","article-title":"One year of romosozumab followed by two years of denosumab maintains fracture risk reductions: results of the FRAME extension study","volume":"34","author":"Lewiecki","year":"2019","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.regg.2024.101582_bib0795","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1007\/s00223-023-01079-y","article-title":"Comparison of the efficacy of zoledronate acid or denosumab after switching from romosozumab in japanese postmenopausal patients","volume":"112","author":"Oue","year":"2023","journal-title":"Calcif Tissue Int"},{"key":"10.1016\/j.regg.2024.101582_bib0800","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1016\/S0140-6736(17)31613-6","article-title":"Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial","volume":"390","author":"Langdahl","year":"2017","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.regg.2024.101582_bib0805","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1210\/clinem\/dgaa756","article-title":"Fracture risk and management of discontinuation of denosumab therapy: a systematic review and position statement by ECTS","volume":"106","author":"Tsourdi","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.regg.2024.101582_bib0810","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1359\/jbmr.090716","article-title":"Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy","volume":"25","author":"Kendler","year":"2010","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.regg.2024.101582_bib0815","doi-asserted-by":"crossref","first-page":"3163","DOI":"10.1210\/jc.2016-1801","article-title":"Denosumab or zoledronic acid in postmenopausal women with osteoporosis previously treated with oral bisphosphonates","volume":"101","author":"Miller","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.regg.2024.101582_bib0820","doi-asserted-by":"crossref","first-page":"3299","DOI":"10.1111\/jgs.19151","article-title":"Unleashing frailty from laboratory into real world: a critical step toward frailty-guided clinical care of older adults","volume":"72","author":"Kim","year":"2024","journal-title":"J Am Geriatr Soc"}],"container-title":["Revista Espa\u00f1ola de Geriatr\u00eda y Gerontolog\u00eda"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0211139X24001161?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0211139X24001161?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,3]],"date-time":"2025-05-03T08:48:30Z","timestamp":1746262110000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0211139X24001161"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":82,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["S0211139X24001161"],"URL":"https:\/\/doi.org\/10.1016\/j.regg.2024.101582","relation":{},"ISSN":["0211-139X"],"issn-type":[{"value":"0211-139X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of osteoporosis treatment in older adults. Approach for the secondary prevention of fractures in older populations. A proposal by SEFRAOS","name":"articletitle","label":"Article Title"},{"value":"Revista Espa\u00f1ola de Geriatr\u00eda y Gerontolog\u00eda","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.regg.2024.101582","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 SEGG. Published by Elsevier Espa\u00f1a, S.L.U. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"101582"}}